6 Cardiology Headlines You Missed in July 2026

After a quiet June, cardiology came roaring back for a full slate in July 2026. The US Food and Drug Administration produced a slew of approvals for key devices and medications in dyslipidemia and heart failure (HF), while the SYMPHONY-PE trial demonstrated the value of early mechanical thrombectomy in improving cardiovascular health without impacting safety in patients with pulmonary embolism. Additionally, the American Heart Association (AHA) and the American College of Cardiology (ACC) released the first-ever clinical treatment guidelines for cardiovascular-kidney-metabolic (CKM) syndrome, paving a way forward for the treatment of this prolific condition.

As July 2026 draws to a close, the editorial team at HCPLive has collected 6 of the most impactful must-know headlines for the past 31 days. Get up to speed on anything that may have slipped through the cracks for you below:

FDA News

FDA Approves Enlicitide for LDL-C Lowering in Adults With Hypercholesterolemia

On July 16, 2026, the FDA announced its approval of enlicitide 20 mg tablets under the brand name Lipfendra for LDL-C lowering in adults with hypercholesterolemia and heterozygous familial hypercholesterolemia (HeFH). The decision was supported by the CORALreef Lipids and CORALreef HeFH trials, which both demonstrated substantial reductions in LDL-C, non-HDL-C, and ApoB compared to increases with placebo.

FDA Approves Furosemide Injection (Furoscix ReadyFlow) for Edema in HF, CKD

MannKind’s Furoscix ReadyFlow, a full 80 mg/dL dose of subcutaneous furosemide delivered via an autoinjector in <10 seconds, was approved by the FDA on July 24, 2026. The basis for the approval, a collection of clinical data demonstrating furosemide’s efficacy, optimal bioavailability, and positive tolerability and safety, also demonstrated equivalent urine output, sodium excretion, and potassium secretion at 6, 8, and 12 hours versus intravenous furosemide.

CaRi-Heart Receives FDA De Novo Authorization for Coronary Inflammation

The FDA granted De Novo authorization to the CaRi-Heart device to quantify coronary inflammation from routine coronary CT angiography (CCTA) on July 29, 2026. The device applies AI analysis to CCTA images, searching for inflammation-related changes in the fat surrounding the coronary arteries. The device then quantifies these changes as the fat attenuation index score, a proprietary biomarker of coronary inflammation, and generates the CaRi-Heart Risk score, an estimation of a patient’s 10-year cardiovascular mortality risk. Parent company Caristo plans to launch CaRi-Heart commercially in the US during Q3 2026 and will expand availability through the end of the year.

Trial Results

AXIOMATIC-TKR: Milvexian Decouples Thrombosis, Hemostasis in DVT

A new analysis of the AXIOMATIC-TKR trial highlighted milvexian’s capacity for inhibiting intrinsic pathway thrombin generation (TG) without impacting extrinsic pathway TG, effectively decoupling thrombosis from hemostasis in patients with deep-vein thrombosis (DVT). The trial demonstrated that milvexian successfully reduced venous thromboembolism in patients undergoing an elective unilateral total knee arthroplasty.

SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes

The SYMPHONY-PE trial, a prospective, multicenter, single-arm interventional study evaluating the Symphony Thrombectomy System from Imperative Care in patients with acute, intermediate-risk pulmonary embolism (PE), has demonstrated the safety of early mechanical thrombectomy compared to late thrombectomy. The earlier the intervention, the trial suggests, the greater the cardiovascular improvement, without a substantial effect on safety event rates.

Guideline Updates

AHA, ACC Release First-Ever Cardiovascular-Kidney-Metabolic Syndrome Guidelines

The newly released guidelines for CKM Syndrome from the AHA and ACC fully replace the 2013 Guideline for the Management of Overweight and Obesity, recommending a complete overhaul in how the prolific disease is managed. CKM syndrome staging is now recommended in all adolescents and adults to prevent progression and reduce cardiovascular events, while the PREVENT equations have once more taken center stage as the tool to evaluate atherosclerotic cardiovascular disease (ASCVD), HF, and total cardiovascular disease risk. Additionally, the guidelines emphasize the need for interdisciplinary care, treatment for overweight or obesity, and assessment of potential chronic kidney disease.